Russian pharmaceutical company PSK Pharma has registered Tirzero Slim (tirzepatide), the third analogue of Mounjaro, the popular type 2 diabetes and obesity drug made by US drug giant Eli Lilly. According to an entry in the state medicines registry, the pharmaceutical substance for the domestic product is manufactured by China’s Hubei GXBio Pharmaceutical Co., Ltd.
The drug is a once-weekly injectable solution and has been registered in six dosages ranging from 2.5 mg to 15 mg.
The original tirzepatide is manufactured by US-based Eli Lilly. The drug has been approved to treat type 2 diabetes, manage weight and treat obesity. However, Eli Lilly’s product was never registered in Russia. In January 2025, Russian drugmaker Promomed registered a version of the original under the brand Tirzetta. In April of that year, another domestic manufacturer, Geropharm, received a registration certificate for a product with the same active ingredient under the name Sejaro.
R-Pharm has also obtained permission to conduct trials of tirzepatide. In addition, Promomed has launched a clinical study to evaluate the efficacy and safety of tirzepatide for treating obesity and overweight in adolescents.
Demand for semaglutide and tirzepatide analogues is growing rapidly in Russia. According to data from the Honest Mark traceability system, Russian pharmaceutical companies produced 11.7 million packs of such drugs in 2025 — ten times the total volume of semaglutide imported between 2020 and 2023.
